Diagnostic and prognostic impact of serum-soluble UL16-binding protein 2 in lung cancer patients

Cancer Science

Volumn 103, Issue 8, 2012, Pages 1405-1413

  Yamaguchi, Kosuke ^a   Chikumi, Hiroki ^a   Shimizu, Asuka ^a   Takata, Miyako ^a   Kinoshita, Naoki ^a   Hashimoto, Kiyoshi ^a   Nakamoto, Masaki ^a   Matsunaga, Shinji ^a   Kurai, Jun ^a   Miyake, Naomi ^a   Matsumoto, Shingo ^a   Watanabe, Masanari ^a   Yamasaki, Akira ^a   Igishi, Tadashi ^a   Burioka, Naoto ^a   Shimizu, Eiji ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMIUM 51; MEMBRANE PROTEIN; NATURAL KILLER CELL RECEPTOR NKG2D; UL16 BINDING PROTEIN 2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER PATIENT; CONTROLLED STUDY; CYTOTOXICITY TEST; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SUPERNATANT;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CYTOTOXICITY TESTS, IMMUNOLOGIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GPI-LINKED PROTEINS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84864314747     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2012.02330.x     Document Type: Article

References (48)

1. Baba T, Hanagiri T, Ichiki Y et al. Lack and restoration of sensitivity of lung cancer cells to cellular attack with special reference to expression of human leukocyte antigen class I and/or major histocompatibility complex class I chain related molecules A/B. Cancer Sci 2007; 98: 1795-802.
2. Smyth MJ, Hayakawa Y, Takeda K, Yagita H. New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer 2002; 2: 850-61.
3. Gonzalez S, Lopez-Soto A, Suarez-Alvarez B, Lopez-Vazquez A, Lopez-Larrea C. NKG2D ligands: key targets of the immune response. Trends Immunol 2008; 29: 397-403.
4. Borchers MT, Harris NL, Wesselkamper SC et al. The NKG2D-activating receptor mediates pulmonary clearance of Pseudomonas aeruginosa. Infect Immun 2006; 74: 2578-86.
5. Bauer S, Groh V, Wu J et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999; 285: 727-9.
6. Nausch N, Cerwenka A. NKG2D ligands in tumor immunity. Oncogene 2008; 27: 5944-58.
7. Champsaur M, Lanier LL. Effect of NKG2D ligand expression on host immune responses. Immunol Rev 2010; 235: 267-85.
8. Bahram S, Bresnahan M, Geraghty DE, Spies T. A second lineage of mammalian major histocompatibility complex class I genes. Proc Natl Acad Sci USA 1994; 91: 6259-63.
9. Cosman D, Mullberg J, Sutherland CL et al. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 2001; 14: 123-33.
10. Dunn C, Chalupny NJ, Sutherland CL et al. Human cytomegalovirus glycoprotein UL16 causes intracellular sequestration of NKG2D ligands, protecting against natural killer cell cytotoxicity. J Exp Med 2003; 197: 1427-39.
11. Bacon L, Eagle RA, Meyer M, Easom N, Young NT, Trowsdale J. Two human ULBP/RAET1 molecules with transmembrane regions are ligands for NKG2D. J Immunol 2004; 173: 1078-84.
12. Salih HR, Holdenrieder S, Steinle A. Soluble NKG2D ligands: prevalence, release, and functional impact. Front Biosci 2008; 13: 3448-56.
13. Groh V, Bahram S, Bauer S, Herman A, Beauchamp M, Spies T. Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc Natl Acad Sci USA 1996; 93: 12445-50.
14. Kraetzel K, Stoelcker B, Eissner G et al. NKG2D-dependent effector function of bronchial epithelium-activated alloreactive T-cells. Eur Respir J 2008; 32: 563-70.
15. Pende D, Rivera P, Marcenaro S et al. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res 2002; 62: 6178-86.
16. Maccalli C, Pende D, Castelli C, Mingari MC, Robbins PF, Parmiani G. NKG2D engagement of colorectal cancer-specific T cells strengthens TCR-mediated antigen stimulation and elicits TCR independent anti-tumor activity. Eur J Immunol 2003; 33: 2033-43.
17. Chen XM, Xu XQ, Sun K, Hallett WH, Zhao JD, Zhang DL. NKG2D ligands expression and NKG2D-mediated cytotoxicity in human laryngeal squamous carcinoma cells. Scand J Immunol 2008; 67: 441-7.
18. Le Maux Chansac B, Misse D, Richon C et al. Potentiation of NK cell-mediated cytotoxicity in human lung adenocarcinoma: role of NKG2D-dependent pathway. Int Immunol 2008; 20: 801-10.
19. Salih HR, Rammensee HG, Steinle A. Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. J Immunol 2002; 169: 4098-102.
20. Salih HR, Goehlsdorf D, Steinle A. Release of MICB molecules by tumor cells: mechanism and soluble MICB in sera of cancer patients. Hum Immunol 2006; 67: 188-95.
21. Waldhauer I, Steinle A. Proteolytic release of soluble UL16-binding protein 2 from tumor cells. Cancer Res 2006; 66: 2520-6.
22. Salih HR, Antropius H, Gieseke F et al. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood 2003; 102: 1389-96.
23. Rebmann V, Schutt P, Brandhorst D et al. Soluble MICA as an independent prognostic factor for the overall survival and progression-free survival of multiple myeloma patients. Clin Immunol 2007; 123: 114-20.
24. Wu JD, Higgins LM, Steinle A, Cosman D, Haugk K, Plymate SR. Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. J Clin Invest 2004; 114: 560-8.
25. Li K, Mandai M, Hamanishi J et al. Clinical significance of the NKG2D ligands, MICA/B and ULBP2 in ovarian cancer: high expression of ULBP2 is an indicator of poor prognosis. Cancer Immunol Immunother 2009; 58: 641-52.
26. Lu SM, Xiao P, Xue L et al. Prevalent expression of MHC class I chain-related molecule A in human osteosarcoma. Neoplasma 2008; 55: 266-72.
27. Paschen A, Sucker A, Hill B et al. Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B. Clin Cancer Res 2009; 15: 5208-15.
28. Raffaghello L, Prigione I, Airoldi I et al. Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma. Neoplasia 2004; 6: 558-68.
29. Marten A, von Lilienfeld-Toal M, Buchler MW, Schmidt J. Soluble MIC is elevated in the serum of patients with pancreatic carcinoma diminishing gammadelta T cell cytotoxicity. Int J Cancer 2006; 119: 2359-65.
30. Arreygue-Garcia NA, Daneri-Navarro A, del Toro-Arreola A et al. Augmented serum level of major histocompatibility complex class I-related chain A (MICA) protein and reduced NKG2D expression on NK and T cells in patients with cervical cancer and precursor lesions. BMC Cancer 2008; 8: 16.
31. Jinushi M, Takehara T, Tatsumi T et al. Impairment of natural killer cell and dendritic cell functions by the soluble form of MHC class I-related chain A in advanced human hepatocellular carcinomas. J Hepatol 2005; 43: 1013-20.
32. Kohga K, Takehara T, Tatsumi T et al. Serum levels of soluble major histocompatibility complex (MHC) class I-related chain A in patients with chronic liver diseases and changes during transcatheter arterial embolization for hepatocellular carcinoma. Cancer Sci 2008; 99: 1643-9.
33. Tamaki S, Sanefuzi N, Kawakami M et al. Association between soluble MICA levels and disease stage IV oral squamous cell carcinoma in Japanese patients. Hum Immunol 2008; 69: 88-93.
34. Kurai J, Chikumi H, Hashimoto K et al. Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin Cancer Res 2007; 13: 1552-61.
35. Mayor S. Analysis of the cell-surface distribution of GPI-anchored proteins. Methods Mol Biol 1999; 116: 23-36.
36. Borchers MT, Harris NL, Wesselkamper SC, Vitucci M, Cosman D. NKG2D ligands are expressed on stressed human airway epithelial cells. Am J Physiol Lung Cell Mol Physiol 2006; 291: L222-31.
37. Holdenrieder S, Stieber P, Peterfi A, Nagel D, Steinle A, Salih HR. Soluble MICA in malignant diseases. Int J Cancer 2006; 118: 684-7.
38. Holdenrieder S, Stieber P, Peterfi A, Nagel D, Steinle A, Salih HR. Soluble MICB in malignant diseases: analysis of diagnostic significance and correlation with soluble MICA. Cancer Immunol Immunother 2006; 55: 1584-9.
39. Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002; 419: 734-8.
40. Song H, Kim J, Cosman D, Choi I. Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression. Cell Immunol 2006; 239: 22-30.
41. Groh V, Smythe K, Dai Z, Spies T. Fas-ligand-mediated paracrine T cell regulation by the receptor NKG2D in tumor immunity. Nat Immunol 2006; 7: 755-62.
42. Dai Z, Turtle CJ, Booth GC et al. Normally occurring NKG2D+CD4+ T cells are immunosuppressive and inversely correlated with disease activity in juvenile-onset lupus. J Exp Med 2009; 206: 793-805.
43. Kaiser BK, Yim D, Chow IT et al. Disulphide-isomerase-enabled shedding of tumour-associated NKG2D ligands. Nature 2007; 447: 482-6.
44. Fernandez-Messina L, Ashiru O, Boutet P et al. Differential mechanisms of shedding of the glycosylphosphatidylinositol (GPI)-anchored NKG2D ligands. J Biol Chem 2010; 285: 8543-51.
45. Dohmoto K, Hojo S, Fujita J et al. Mechanisms of the release of CYFRA21-1 in human lung cancer cell lines. Lung Cancer 2000; 30: 55-63.
46. Takada M, Masuda N, Matsuura E et al. Measurement of cytokeratin 19 fragments as a marker of lung cancer by CYFRA 21-1 enzyme immunoassay. Br J Cancer 1995; 71: 160-5.
47. Nisman B, Biran H, Ramu N, Heching N, Barak V, Peretz T. The diagnostic and prognostic value of ProGRP in lung cancer. Anticancer Res 2009; 29: 4827-32.
48. Travis WD. Update on small cell carcinoma and its differentiation from squamous cell carcinoma and other non-small cell carcinomas. Mod Pathol 2012; 25(Suppl 1): S18-30.